Le Lézard
Classified in: Health, Business
Subjects: TRI, FDA

Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA


INCHEON, South Korea, Jan. 26, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced another successful Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy, furthering the company's track record as a premiere CDO service provider in the global market.

In late 2018, National OncoVenture (NOV), a government-funded virtual oncology drug development program in South Korea, approached Samsung Biologics for the development of EU101(NOV1801), an anti-4-1BB therapeutic monoclonal antibody provided by Eutilex (KOSDAQ:263050). Studied by NOV and Eutilex with humanized mice, EU101(NOV1801), effectively eradicated human tumors and showed synergistic anti-tumor activity with immune checkpoint blockade.

"We are extremely glad to be notified of EU101(NOV1801)'s IND approval from the FDA," said John Rim, CEO of Samsung Biologics. "This is our third IND approval demonstrating our unparalleled quality and speed, and as our CDO business continues to expand geographically in the next decade, we look forward to assisting many more clients in bringing their products to market faster and better as the most qualified CDMO partner."

Young-Whan Park, president of NOV, said, "In order to conduct the domestic and global clinical trials of EU101(NOV1801) in parallel, we plan to file another IND with the Ministry of Food and Drug Safety in South Korea within the first half of this year, working together with Samsung Biologics." Dr. Soo Young Choi, COO of Eutilex, added, "In the US, we will be able to determine the Maximum Tolerated Dose (MTD) and Recommended Phase II Dose (RP2D) through Phase I of clinical trials within the first half of the year."

Samsung Biologics' CDO business has shown rapid growth and success since its business expansion, signing over 60 CDO contracts within two years to obtain three IND approvals by the FDA as well as one Clinical Trial Application (CTA) approval by the EMA. Leveraging Samsung Biologics' extensive expertise for the submission process, the successful IND was achieved with no further significant comments from the regulatory agency.

About Samsung Biologics Co., Ltd.

Samsung Biologics (KRX: 207940.KS) is a fully integrated CDMO offering state-of-the-art contract development, manufacturing, and laboratory testing services. With proven regulatory approvals, the largest capacity, and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is uniquely able to support the development and manufacturing of biologics products at every stage of the process while meeting the evolving needs of biopharmaceutical companies worldwide. For more information, visit www.samsungbiologics.com.

About Eutilex, Ltd.

Eutilex (KOSDAQ:263050) is a biotechnology company focused on the research and development of three in-house immunotherapeutic platforms, including innovative T cell receptor (TCR) T cell therapy, chimeric antigen receptor (CAR) T cell therapy and immunomodulatory antibody therapeutics, to help lead the fight against incurable diseases such as cancers. The mission of Eutilex is a dedication to develop and deliver innovative immune-oncology therapeutics to patients in desperate need.

Samsung Biologics Press Contact

Claire Kim
[email protected]

SOURCE Samsung Biologics


These press releases may also interest you

at 08:33
A healthy lifestyle consists of multiple good habits and activities. Quality sleep and consistent exercise are critical factors in keeping the body healthy. So is nutrition. A well-balanced diet (including both food and supplements) helps give the...

at 08:31
Arctic Blue is a fish oil brand that specializes in producing clean, high-quality, full-spectrum fish oil from wild cod caught in the Barents Sea between Novaya Zembla, Spitsbergen and Northern Norway. The oil is known for its soft, smooth taste and...

at 08:31
Arctic Blue's fish oil supplements are sourced from fish oil harvested from some of the cleanest water in the world. Its cod are caught in the Barents Sea and their oil is sustainably sourced from fillet trimmings, often processed right on the boat...

at 08:20
In celebration of National Doctors' Day on March 30, patients across the country are sharing personal stories about how their MDVIP-affiliated primary care physician has made a difference in their life. MDVIP collected and will deliver to its network...

at 08:17
AMIGOS FOR KIDS, a Miami nonprofit organization founded in 1991, is dedicated to preventing child abuse and neglect by valuing children, strengthening families and educating communities. ...

at 08:15
Maverix Medical, a dedicated lung cancer platform established by Ajax Health, KKR, and Hologic, Inc., today announced the acquisition of Cirrus Bio for an undisclosed amount....



News published on and distributed by: